Neurent gets €25M to scale chronic-rhinitis treatment

Neurent Medical's financing is another example of commercial-stage medtech using debt rather than relying only on venture equity to scale.

What happened

Neurent Medical secured a €25 million growth-debt facility from Claret Capital Partners. The financing will support commercial expansion of its NEUROMARK system for chronic rhinitis and follows a €62.5 million Series C earlier in 2026.

Why it matters

Once a medical device has reached the market, the capital need shifts toward sales, distribution and working capital. Debt can finance that expansion without creating the same dilution as another large equity round.

The bigger picture

Medtech companies increasingly need different pools of capital at different stages: venture funding for product development and regulatory work, then structured debt or growth capital as commercial rollout accelerates.